Dynavax Technologies | DVAX - Assets



Dynavax Technologies reported $918.45M in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Adma Biologics USD 558.38M 69.7M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Dynavax Technologies USD 918.45M 27.48M Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
Glaxosmithkline GBP 59.26B 205M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Roche Holding CHF 101.8B 6.02B Dec/2024
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
TG Therapeutics USD 702.61M 45.92M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025